and recommendation
Cytori Therapeutics, Inc. (CYTX)
Cytori Therapeutics, Inc. develops cellular therapeutics for specific diseases and medical conditions.
CYTX primarily provides Cytori Cell Therapy, which is in Phase III pivotal clinical trial for the treatment of impaired hand function in scleroderma.
CYTX offers Celution System devices, proprietary enzymes, and sterile consumable sets that are used at the point-of-therapeutic application or at an off-site processing center; and StemSource cell and tissue banking systems, as well as surgical accessories and instruments.
CYTX also provides ATI-0918, a liposomal encapsulation of doxorubicin for use in treating breast cancer, ovarian cancer, multiple myeloma, and Kaposi's sarcoma; and ATI-1123, a liposomal formulation of docetaxel for the treatment of non-small cell lung cancer, breast cancer, squamous cell carcinoma of the head and neck cancer, gastric adenocarcinoma, and hormone refractory prostate cancer.
The company was founded in 1996 and is headquartered in San Diego, California.
- October 25, 2012 - 7:26am | Regulatory
- October 23, 2012 - 7:15am | Regulatory
- October 11, 2012 - 7:46am | Regulatory
- October 5, 2012 - 10:25am | Research Notes
- October 2, 2012 - 7:59am | Research Notes
- October 1, 2012 - 3:24pm | Research Notes
- September 28, 2012 - 7:18am | Research Notes
- September 23, 2012 - 10:11am | Research Notes
- September 13, 2012 - 7:36am | Regulatory
- September 10, 2012 - 9:05am | Research Notes
- August 16, 2012 - 8:08am | Scoreboard at a Glance
- August 9, 2012 - 10:48am | Regulatory
- August 8, 2012 - 4:26pm | Earnings
- August 3, 2012 - 7:50am
- June 22, 2012 - 6:19am | Research Notes
- May 30, 2012 - 7:47am | Regulatory
- May 17, 2012 - 2:07pm | Research Notes
- May 16, 2012 - 9:07am | Scoreboard at a Glance
- May 9, 2012 - 4:24pm | Earnings
- March 16, 2012 - 7:16am